China Shineway Pharmaceutical Group Limited (C1S) — Capital Reinvestment Ratio
China Shineway Pharmaceutical Group Limited (C1S) has a Capital Reinvestment Ratio of 0.15x as of June 2023, meaning it reinvests 0% of its operating cash flow (€160.69 Million) in capital expenditures (€24.57 Million). See China Shineway Pharmaceutical Group Limi free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
China Shineway Pharmaceutical Group Limited Capital Reinvestment Ratio (2013–2025)
This chart tracks China Shineway Pharmaceutical Group Limited's Capital Reinvestment Ratio across 13 annual periods.
Annual Capital Reinvestment Ratio for China Shineway Pharmaceutical Group Limited (2013–2025)
Year-by-year Capital Reinvestment Ratio for China Shineway Pharmaceutical Group Limited from 2013 to 2025. For live market cap and broader valuation context, see C1S stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.17x | €1.17 Billion | €197.91 Million | ▲ +16.1% |
| 2024 | 0.15x | €963.13 Million | €140.11 Million | ▼ -6.0% |
| 2023 | 0.15x | €932.63 Million | €144.32 Million | ▲ +32.6% |
| 2022 | 0.12x | €1.11 Billion | €129.46 Million | ▼ -12.4% |
| 2021 | 0.13x | €703.15 Million | €93.63 Million | ▲ +28.8% |
| 2020 | 0.10x | €638.57 Million | €66.03 Million | ▼ -57.0% |
| 2019 | 0.24x | €368.00 Million | €88.40 Million | ▲ +0.5% |
| 2018 | 0.24x | €532.59 Million | €127.34 Million | ▲ +27.8% |
| 2017 | 0.19x | €490.65 Million | €91.83 Million | ▲ +28.5% |
| 2016 | 0.15x | €733.53 Million | €106.79 Million | ▲ +1.7% |
| 2015 | 0.14x | €744.71 Million | €106.56 Million | ▲ +6.2% |
| 2014 | 0.13x | €773.16 Million | €104.18 Million | ▼ -73.3% |
| 2013 | 0.50x | €519.89 Million | €261.89 Million | — |